Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI 779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572
NEURO-ONCOLOGY(2009)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
NEURO-ONCOLOGY(2009)